This report focuses on the global Huntington’s Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Huntington’s Disease Treatment development in United States, Europe and China.
Medications for movement disorders. Drugs to treat movement disorders include the following: Tetrabenazine (Xenazine) is specifically approved by the Food and Drug Administration to suppress the involuntary jerking and writhing movements (chorea) associated with Huntington's disease.
Increased uptake of improved symptomatic therapies, promising disease-modifying therapies in the developmental pipeline, rise in target population, and favorable government initiatives are some of the key factors contributing to market growth.
In 2017, the global Huntington’s Disease Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.
The key players covered in this study
Wave Life Sciences
Ionis Pharmaceuticals/ Roche
Market segment by Type, the product can be split into
Market segment by Application, split into
Ambulatory Surgical Centers
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Huntington’s Disease Treatment status, future forecast, growth opportunity, key market and key players.
To present the Huntington’s Disease Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Huntington’s Disease Treatment are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.